BLB-201 / CyanVac LLC - LARVOL DELTA

A Study of BLB-201 RSV Vaccine in Infants and Children (clinicaltrials.gov) - P1/2 | N=137 | Recruiting | Sponsor: Blue Lake Biotechnology Inc. | Trial completion date: Dec 2026 ➔ Jul 2028 | Trial primary completion date: Dec 2026 ➔ Jul 2028

Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of BLB-201 RSV Vaccine in Infants and Children (clinicaltrials.gov) - P1/2 | N=137 | Recruiting | Sponsor: Blue Lake Biotechnology Inc. | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Sep 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of BLB-201 RSV Vaccine in Infants and Children (clinicaltrials.gov) - P1/2 | N=137 | Recruiting | Sponsor: Blue Lake Biotechnology Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of BLB-201 RSV Vaccine in Infants and Children (clinicaltrials.gov) - P1/2 | N=137 | Active, not recruiting | Sponsor: Blue Lake Biotechnology Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study. (PubMed, Sci Adv) - "Peripheral blood RSV F-specific CD4 and CD8 T cells increased from ≤0.06% at baseline to ≥0.26 and 0.4% after vaccination, respectively, in >93% participants. The safety and immunogenicity profile of BLB201 in RSV-seropositive adults supports the further clinical development of BLB201."

Journal • P1 data • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • CD4 • CD8

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Blue Lake Biotechnology Inc. | Active, not recruiting ➔ Completed | Trial primary completion date: Jun 2023 ➔ Dec 2022

Trial completion • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of BLB-201 RSV Vaccine in Infants and Children (clinicaltrials.gov) - P1/2 | N=150 | Recruiting | Sponsor: Blue Lake Biotechnology Inc. | Initiation date: Jun 2023 ➔ Mar 2023 | Not yet recruiting ➔ Recruiting

Enrollment open • Trial initiation date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of BLB-201 RSV Vaccine in Infants and Children (clinicaltrials.gov) - P1/2 | N=150 | Recruiting | Sponsor: Blue Lake Biotechnology Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of BLB-201 RSV Vaccine in Infants and Children (clinicaltrials.gov) - P1/2 | N=150 | Not yet recruiting | Sponsor: Blue Lake Biotechnology Inc. | Trial completion date: May 2024 ➔ Dec 2024 | Trial primary completion date: Apr 2023 ➔ Sep 2024

Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Blue Lake Biotechnology Inc. | Completed ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Jun 2023 | Trial primary completion date: Nov 2022 ➔ Jun 2023

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of BLB-201 RSV Vaccine in Infants and Children (clinicaltrials.gov) - P1/2 | N=150 | Not yet recruiting | Sponsor: Blue Lake Biotechnology Inc.

New P1/2 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Blue Lake Biotechnology Inc. | Recruiting ➔ Completed | Trial completion date: Apr 2023 ➔ Dec 2022

Trial completion • Trial completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Blue Lake Biotechnology Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Apr 2022 ➔ Jul 2022 | Trial primary completion date: Jul 2022 ➔ Oct 2022

Enrollment open • Trial initiation date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections